<DOC>
	<DOCNO>NCT01455103</DOCNO>
	<brief_summary>The purpose study evaluate pharmacodynamic change BMS-936559 treatment biomarkers measure peripheral blood tumor tissue subject unresectable Stage III IV Melanoma .</brief_summary>
	<brief_title>Phase 1 Biomarker Study Anti-PDL-1 Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Men woman â‰¥ 18 year Eastern Cooperative Oncology Group ( ECOG ) status = 0 1 Subjects unresectable Stage III IV Melanoma either refractory intolerant , refuse standard therapy treatment metastatic Melanoma Subject must histologic cytologic confirmation advance Melanoma Subjects must least one measurable lesion baseline compute tomography ( CT ) magnetic resonance imaging ( MRI ) per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criteria Subjects must least 1 tumor site biopsied acceptable clinical risk must consent pre posttreatment biopsy Active progress brain metastasis Other concomitant malignancy ( exception per protocol ) Active history autoimmune disease Positive test human immunodeficiency virus ( HIV ) 1 &amp; 2 know acquire immunodeficiency syndrome ( AIDS ) History hepatitis Prior therapy antibody/drug target T cell coregulatory protein , include limited , anti Programmed cell death 1 ( PD1 ) , anti Programmed cell death ligand 1 ( antiPDL1 ) , antiPDL2 , antiCD137 , antiOX40 , antiCD40 anti Cytotoxic T lymphocyteassociated antigen 4 ( antiCTLA4 ) antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>